重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎的疗效分析OACSTPCD
Curative effect of type Ⅱ human recombinant of tumor necrosis factor receptor antibody fusion protein in the treatment of rheumatoid arthritis
目的 探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白不同剂量治疗类风湿关节炎的疗效.方法 选取本院自2009年2月至2012年8月收治的类风湿关节炎活动期患者118例,根据患者意愿随机分为治疗组与对照组,每组均为59例,治疗组采取高剂量重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对患者进行治疗,对照组采取低剂量重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗,观察2组患者治疗后的疗效情况.结果 ①治疗组显效48例(81.35％)多于对照组显效17例(2…查看全部>>
Objective To explore the curative effect of type Ⅱ human recombinant of tumor necrosis factor receptor-antibody fusion protein in the treatment of rheumatoid arthritis.Methods One hundred and eighteen cases in our hospital from February 2009 to August 2012 with active rheumatoid arthritis were selected and divided randomly into treatment group and control group,59 cases in each.The treatment group was applied with high doses of recombinant human tumor necros…查看全部>>
姚朝琼
四川省达州市中心医院综合科,四川达州,635000
医药卫生
重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白类风湿关节炎疗效
type Ⅱ human recombinant of tumor necrosis factor receptor antibody fusion protein rheumatoid arthritis curative effect
《实用临床医药杂志》 2013 (16)
12-14,3
评论